Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
作者信息
Singla Nirmish, Margulis Vitaly
机构信息
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
出版信息
Eur Urol. 2020 Aug;78(2):e79-e80. doi: 10.1016/j.eururo.2020.04.025. Epub 2020 Apr 30.
PMID:32362497
Abstract
摘要
相似文献
1
Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.回复：杰拉尔丁·皮尼奥、安托万·蒂埃里 - 维勒明、约亨·瓦尔兹等。转移性肾细胞癌对免疫检查点抑制剂完全缓解后的肾切除术：一项新的外科挑战？《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2019.12.018：肾癌的下一个外科前沿：免疫检查点抑制后的肾切除术
Eur Urol. 2020 Aug;78(2):e79-e80. doi: 10.1016/j.eururo.2020.04.025. Epub 2020 Apr 30.
2
Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.回复尼米什·辛格拉和维塔利·马尔古利斯致编辑的信，信中涉及：杰拉尔丁·皮尼奥、安托万·蒂埃里 - 维勒明、约亨·瓦尔兹等人。转移性肾细胞癌对免疫检查点抑制剂完全缓解后的肾切除术：一项新的手术挑战？《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2019.12.018。肾癌的下一个手术前沿：免疫检查点抑制后的肾切除术：免疫治疗后的肾切除术：治疗暴露时间可能起决定性作用。
Eur Urol. 2020 Aug;78(2):e81-e82. doi: 10.1016/j.eururo.2020.04.052. Epub 2020 May 7.
3
Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?回复：比马尔·宾迪、杰弗里·格雷厄姆、J·康纳·韦尔斯等人。初诊转移性肾细胞癌患者的延期减瘤性肾切除术。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.04.038：减瘤性肾切除术：适用于谁以及何时进行？
Eur Urol Oncol. 2020 Aug;3(4):559-560. doi: 10.1016/j.euo.2020.05.011. Epub 2020 Jun 15.
4
Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?回复：森庆一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔菲等人。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.10.006：免疫检查点抑制剂的临床活性：宿主是答案吗？
Eur Urol. 2021 Apr;79(4):e112. doi: 10.1016/j.eururo.2021.01.013. Epub 2021 Jan 29.
5
Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?回复约翰娜·诺埃尔、奥利维耶·于利亚尔和弗朗索瓦·戈德瓦塞尔致编辑的信，信的内容涉及：森英一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔菲等人的《程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析》。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.10.006。免疫检查点抑制剂的临床活性：宿主是答案吗？
Eur Urol. 2021 Apr;79(4):e113-e114. doi: 10.1016/j.eururo.2021.01.012. Epub 2021 Jan 21.
6
Re: Longbin Xiong, Jane K. Nguyen, Yulu Peng, et al. What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy? Eur Urol. 2022;81:492-500. https://doi.org/10.1016/j.eururo.2021.12.036.回复：熊龙斌、简·K·阮、彭雨露等。肾部分切除术夹闭后保留的肾实质会发生什么？《欧洲泌尿外科杂志》。2022年；81卷：492 - 500页。https://doi.org/10.1016/j.eururo.2021.12.036 。
Eur Urol. 2022 Aug;82(2):e49. doi: 10.1016/j.eururo.2022.04.021. Epub 2022 May 13.
7
Reply to Mengda Zhang and Long Wang's Letter to the Editor re: Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, et al. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥ 10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.11.024.回复张孟达和王龙致编辑的信，信的内容涉及：弗朗切斯科·波尔皮利亚、恩里科·切库奇、达尼埃莱·安帕罗雷等人。复杂肿瘤（PADUA≥10）情况下的三维增强现实机器人辅助部分肾切除术：一种克服超声引导的新型术中工具。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2019.11.024 。
Eur Urol. 2020 Jun;77(6):e163-e164. doi: 10.1016/j.eururo.2020.03.038. Epub 2020 Apr 9.
8
Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.回复：齐亚德·巴库尼、塔拉勒·埃尔·扎里夫、沙恩·杜达尼等人。免疫检查点抑制剂或靶向治疗的转移性肾细胞癌的 upfront 减瘤性肾切除术：来自国际转移性肾细胞癌数据库联盟的一项观察性研究。《欧洲泌尿外科杂志》2023 年；83 卷：145 - 151 页。
Eur Urol. 2023 Sep;84(3):e75. doi: 10.1016/j.eururo.2023.04.040. Epub 2023 Jun 1.
9
Re: Kosuke Takemura, Matthew S. Ernst, Vishal Navani, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.002.回复： Kosuke Takemura、Matthew S. Ernst、Vishal Navani等人。联合免疫治疗时代接受延迟、 upfront或不进行减瘤性肾切除术的转移性肾细胞癌患者的特征：国际转移性肾细胞癌数据库联盟的结果。《欧洲泌尿外科肿瘤学》。即将发表。https://doi.org/10.1016/j.euo.2023.10.002 。
Eur Urol Oncol. 2024 Jun;7(3):642-643. doi: 10.1016/j.euo.2023.12.011. Epub 2024 Jan 17.
10
Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.回复：马克辛·孙、安德烈亚斯·贝克尔、田哲等。局限性肾癌的管理：计算手术和非手术治疗的癌症特异性死亡率及死亡的竞争风险。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2013.03.034
Eur Urol. 2013 Nov;64(5):e105-6. doi: 10.1016/j.eururo.2013.07.023. Epub 2013 Jul 25.
引用本文的文献
1
The clinical efficacy of monolayer suture combined with hem-o-lok clip in partial nephrectomy among patient with renal cell carcinoma: a quasi-experimental study.在肾细胞癌患者的部分肾切除术中，单层缝合联合Hem-o-lok 夹的临床疗效：一项准实验研究。
World J Surg Oncol. 2024 Nov 7;22(1):292. doi: 10.1186/s12957-024-03560-w.
2
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.新辅助纳武利尤单抗治疗非转移性透明细胞肾细胞癌的免疫调节反应。
Sci Rep. 2024 Jan 17;14(1):1458. doi: 10.1038/s41598-024-51889-9.
3
Characterizing Tumor Thrombus Arising from Non-Clear Cell Renal Cell Carcinoma.非透明细胞肾细胞癌来源肿瘤血栓的特征分析
Eur Urol Open Sci. 2022 Jul 25;43:28-34. doi: 10.1016/j.euros.2022.07.001. eCollection 2022 Sep.
Zotero 插件